ECEdvan de Queiroz Crusoe

Edvan de Queiroz Crusoe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Edvan de Queiroz Crusoe has a total of 287 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dysregulation of the Bone Marrow Immune Microenvironment and Clinical Outcomes in Multiple Myeloma

    by Maria P. Ghirardi, Patricia Brandalise, Maria Berraondo, Cristian Seehaus, Danielle Leão, Fernando Vieira Pericole, Roberto J. P. Magalhães, Edvan Crusoé, Angelo Maiolino, Vania Hungria, et al.

    Multiple myeloma (MM) is characterized not only by malignant plasma cell proliferation but also by progressive dysregulation of the bone marrow immune microenvironment (BMIME). Increasing evidence suggests that disease progression, therapeutic resistance, and clinical outcomes are associated with dynamic interactions between tumor cells, immune populations, stromal elements, and inflammatory signaling pathways within the marrow niche. Although many of these observations derive from high-dimensional immune profiling, spatial transcriptomics, and single-cell transcriptomic studies, emerging mechanistic and functional evidence supports an important role for immune dysregulation in shaping disease evolution, immune escape, and therapeutic responsiveness. Recent advances in spatial profiling, immune phenotyping, and multi-omic approaches have revealed profound remodeling of the immune ecosystem across the evolution from monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) to symptomatic MM. This remodeling is characterized by progressive T-cell exhaustion, immunosenescence, dysfunction of natural killer (NK) cells, expansion of immunosuppressive myeloid populations, and altered cytokine and ligand–receptor signaling networks associated with adverse clinical outcomes. Importantly, emerging studies demonstrate that immune signatures derived from the BMIME may improve prognostic stratification beyond conventional tumor cytogenetics and staging systems. In this review, we discuss the mechanisms underlying immune dysregulation in MM, summarize recent discoveries regarding immune remodeling associated with clinical outcomes, and explore the translational implications of immune-based biomarkers and therapeutic strategies. Understanding the dynamic interplay between tumor genetics, immune-cell states, immunosenescence, and microenvironmental remodeling may facilitate the development of clinically actionable biomarkers and more personalized immunotherapeutic approaches and novel risk-adapted treatment strategies in MM.

  • Open Access

    Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma

    by Edvan Q. Crusoé, Glaciano Ribeiro, João Tadeu D. Souto Filho, Jayr Schmidt Filho, Natalia Schutz, Milton A. F. Aranha, Abel Costa, Abrahao Hallack, Fernando V. Pericole, Juliana S. Lima, et al.

  • Open Access

    Brazilian consensus recommendations on the diagnosis and treatment of light chain amyloidosis

    by Pedro Manoel Marques Garibaldi, João Tadeu Damian Souto Filho, Roberto Jose Pessoa de Magalhães Filho, Roberta Shcolnik Szor, Carlos Eduardo Miguel, Edvan Crusoe, Carolina Tosin Bueno, Thiago Queiroz, Vânia Hungria

  • Top Cited Papers
    Open Access

    Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis

    by Efstathios Kastritis, Giovanni Palladini, Monique C Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, Hans C Lee, Vaishali Sanchorawala, Peter Mollee, Jin Lu, Stefan O. Schönland, et al.

    In the primary analysis of ANDROMEDA, addition of subcutaneous daratumumab to bortezomib/cyclophosphamide/dexamethasone (D-VCd) significantly improved hematologic complete response (CR) rate versus VCd, establishing D-VCd as the only approved therapy for light-chain (AL) amyloidosis. We present results from the preplanned final analysis. In this phase 3 trial, we randomly assigned 388 patients with newly diagnosed AL amyloidosis to six cycles of VCd alone (control group) or with subcutaneous daratumumab (D-VCd) followed by single-agent daratumumab every 4 weeks for up to 24 total cycles. The primary endpoint was hematologic CR. The updated hematologic CR rate was 59.5% for D-VCd versus 19.2% for VCd (odds ratio, 6.03; 95% confidence interval [CI], 3.80-9.58; P<0.0001). Median time to hematologic CR was shorter with D-VCd (67.5 days [range, 8.0-879.0]) versus VCd (85.0 days [range, 14.0-617.0]). With a median follow-up of 61.4 months, significant improvement was observed with D-VCd versus VCd in major organ deterioration-progression-free survival (hazard ratio, 0.44; 95% CI, 0.31-0.63; P<0.0001) and overall survival (hazard ratio, 0.62; 95% CI, 0.42-0.90; P=0.0121). Cardiac and renal response rates were 2-3 times higher with D-VCd versus VCd. Achieving hematologic or cardiac CR was associated with improved major organ deterioration-progression-free survival and overall survival. Adverse events were consistent with the known safety profiles for VCd and daratumumab. Adding daratumumab to VCd resulted in deeper and more rapid hematologic responses and recovery of organ function, translating to statistically significant improvement in both overall survival and major organ deterioration-progression-free survival in newly diagnosed AL amyloidosis. ClinicalTrials.gov NCT03201965.


  • Open Access

    Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

    by João Tadeu Damian Souto Filho, Lucas Oliveira Cantadori, Edvan de Queiroz Crusoe, Vania Hungria, Angelo Maiolino

    Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has advanced with anti-CD38 monoclonal antibody (mAb)-based regimens. Although quadruplet combinations incorporating daratumumab and isatuximab have demonstrated improved response rates and progression-free survival (PFS), comparative overall survival (OS) data remain limited. We performed a systematic review, network meta-analysis (NMA), and reconstructed individual patient data meta-analysis comparing survival outcomes of quadruplet versus triplet regimens in TI-NDMM. This study adhered to Cochrane and PRISMA guidelines and was registered prospectively (PROSPERO CRD420251033401). A comprehensive literature search through April 2025 identified randomized clinical trials (RCT) evaluating quadruplet and triplet regimens involving daratumumab, isatuximab, bortezomib, lenalidomide, and dexamethasone in any combination, compared to their backbone regimens, reporting OS and PFS. Four RCT (n = 2,038) were included. At 60 months, estimated PFS rates were: D-VRd (66.4%), I-VRd (63.2%), D-Rd (51.9%), and VRd (42.6%). Both D-VRd and I-VRd significantly improved PFS compared with D-Rd (HR 0.65; 95% CI 0.48-0.87; and HR 0.68; 95% CI 0.52-0.89) and VRd (HR 0.51; 95% CI 0.39-0.67; and HR 0.53; 95% CI 0.41-0.67). D-Rd also showed superior PFS over VRd (HR 0.77, 95% CI 0.64-0.93; P = 0.007). At 60 months, OS rates were: D-VRd (72.8%), I-VRd (72.2%), D-Rd (67.1%), and VRd (67.0%). Pooled analyses demonstrated that quadruplets significantly improved both PFS (64.7% vs. 46.3%; HR 0.57, 95% CI 0.47-0.69; P < 0.0001) and OS (72.5% vs. 67.1%; HR 0.78, 95% CI 0.63-0.96; P = 0.02) compared to triplet regimens. The OS benefit of quadruplets was consistent in comparisons against both D-Rd (HR 0.77; 95% CI: 0.60-0.98; P = 0.04) and VRd (HR 0.77; 95% CI: 0.62-0.97; P = 0.02). In the NMA, quadruplet regimens ranked highest for complete response, PFS, and OS. This meta-analysis supports anti-CD38 mAb-based quadruplet regimens as superior frontline therapy in TI-NDMM, significantly improving overall survival.


  • Open Access

    Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

    by Andrew Spencer, Maria Gavriatopoulou, Daniel Coriu, Anna Lysén, Norma C. Gutiérrez, Fernando Escalante, Dorotea Beatriz Eugenia Fantl, Roman Hájek, Fernanda Seguro, Gurbakhash Kaur, et al.

    Genetic abnormalities in multiple myeloma (MM) influence treatment outcomes and may inform therapeutic decisions. The most common chromosomal translocation in MM is t(11;14); however, its role in disease progression is not well defined. We report results from MEDICI, a global, minimally invasive, prospective study evaluating t(11;14) status in newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM). MEDICI enrolled adult patients (≥18 years) with MM with bone marrow (BM) aspirates collected at diagnosis and/or disease relapse. The primary objective was to determine t(11;14) prevalence in patient BM samples using fluorescent in situ hybridization (FISH) with plasma cell enrichment. Samples from 525 patients (NDMM, n = 306; RRMM, n = 219) were analyzed for t(11;14), with 498 patients (95%) having successful BM FISH test. Prevalence of t(11;14) was 22.1% (110/498 patients; 95% confidence interval [CI], 18.5-26.0) in the overall patient population, 18.8% (56/298 patients; 95% CI, 14.5-23.7) in NDMM, and 27.0% (54/200 patients; 95% CI, 21.0-33.7) in RRMM. Patients with t(11;14)-positive MM were evenly distributed across disease stages (stage I, 24.1%; stage II, 20%; stage III, 21.3%); however, higher rates were observed in African American patients (RRMM odds ratio [OR], 7.27, 95% CI, 1.33-39.83; P = .022) and light-chain only disease (NDMM OR, 3.02, 95% CI, 1.33-6.87; P = .008). Chromosome 1q abnormalities occurred more often in the absence of t(11;14); however, higher frequency of mutation in the plasma cell differentiation regulator IRF4 was detected in t(11;14) presence. In conclusion, the results from MEDICI demonstrated reproducible t(11;14) detection with a real-world prevalence of 22.1% in MM. This trial was registered at www.ClinicalTrials.gov as #NCT04721002.


  • Open Access

    Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

    by João Tadeu Damian Souto Filho, Lucas Oliveira Cantadori, Edvan de Queiroz Crusoe, Vania Hungria, Angelo Maiolino

    The treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (TE-NDMM) has evolved with the introduction of daratumumab-based quadruplet regimens. Adding daratumumab to traditional triplet regimens has demonstrated improved response rates and progression-free survival (PFS). However, the impact on long-term outcomes, particularly overall survival (OS), remains uncertain. This systematic review and meta-analysis aimed to compare the survival outcomes of these quadruplet regimens with triplets. Conducted in adherence to Cochrane Collaboration and PRISMA guidelines and registered on PROSPERO (CRD42024571946), the study involved searching PubMed, Embase, and Cochrane databases, from inception to June 2024. We included randomized clinical trials (RCT) and non-randomized controlled studies (NRCS) that compared daratumumab-based quadruplet regimens to triplets, focusing on OS and PFS, with a minimum follow-up of 18 months. The meta-analysis included 3327 TE-NDMM patients from four studies, comprising three RCT and one NRCS. Daratumumab-based regimens were administered to 1328 (40%) patients. The analysis revealed that daratumumab-based quadruplet regimens significantly improved both OS (pooled HR 0.60; 95% CI 0.48–0.75; P < 0.00001; I² = 0%) and PFS (pooled HR 0.49; 95% CI 0.37–0.65; P < 0.00001; I² = 52%). A per-protocol subgroup analysis comparing D-VRD to VRD further confirmed these benefits, with significant improvements in both OS (pooled HR 0.68; 95% CI 0.48–0.97; P = 0.03; I² = 0%) and PFS (pooled HR 0.41; 95% CI 0.31–0.54; P < 0.00001; I² = 0%). This meta-analysis consolidates evidence that daratumumab-based quadruplet regimens significantly improve OS, compared to triplet regimens for TE-NDMM patients.


  • Open Access

    Health care systems as determinants of outcomes in multiple myeloma: final results from the Latin American MYLACRE study

    by Vania Hungria, Rafael Gaiolla, Kenny Galvez, Guillermina Remaggi, Natalia Schutz, Rosane Bittencourt, Angelo Maiolino, Guillermo Quintero-Vega, Maria Silvana Cugliari, Walter Moises Tobias Braga, et al.

    Although systemic therapy for multiple myeloma (MM) has evolved considerably over the past 2 decades, state-of-the-art treatment is not uniformly available in Latin America. In some countries, disparities between the public and private sectors in clinical presentation, access to novel agents, and transplantation are striking, with the public sector lagging. We conducted a multicenter, observational study of patients with MM in 5 Latin American countries (Argentina, Brazil, Colombia, Mexico, and Panama). We enrolled patients aged ≥18 years diagnosed with MM between January 2016 and June 2021, using data collected between May 2019 and June 2022. We categorized institutions as “public” when primarily funded by federal or local government, and “private” when financed mostly or completely by other sources. We analyzed 1029 patients, 1021 of whom could be classified into public (n = 339) and private (n = 682) institutions. These 2 groups differed in many respects, with patients from the latter having better baseline prognostic features (including eligibility to transplantation) and receiving combinations of immunomodulatory drugs and proteasome inhibitors, as well as anti-CD38 antibodies, more frequently than patients from public institutions. Among 960 patients with complete data for this analysis, the median overall survival was 44.6 months in public institutions and 53.3 months in private institutions (hazard ratio, 0.84; 95% confidence interval, 0.67-1.04; P = .109). Our results indicate diagnostic and therapeutic shortcomings in the management of MM in Latin America, with important gaps in patient profile, treatment patterns and long-term outcomes between public and private institutions. This trial was registered at www.clinicaltrials.gov as #NCT03955900.


  • Open Access

    Phase 2 trial of daratumumab, cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma

    by Edvan de Queiroz Crusoé, Joanna Suzana Leal Ribeiro dos Santos, Juliana de Andrade Santos, Herbert Henrique de Melo Santos, Allan de Souza Santos, Larissa Ferreira Lucas, Cristiane Almeida Requião de Pinna, Paula Nogueira Caldas Freire, Adriano Araujo de Jesus, Alessandro de Moura Almeida, et al.

  • Open Access

    Challenges in the integration of palliative care for patients with hematologic malignancies: an analysis of the surprise question in a prospective cohort study

    by Alini Maria Orathes Ponte Silva, Diego Lopes Paim Miranda, David Pereira Ferreira, Camilla Correia de Araujo Pereira Campos, Edvan de Queiroz Crusoé, Felipe Feistauer Gomes, Thiago Favano, Marco Aurélio Salvino

    BACKGROUND: The Surprise Question (SQ), “Would I be surprised if this patient were to die in the next 12 months?”, identifies patients at high risk of death who might benefit from palliative care (PC). However, little is known about its application in oncohematology.